Promoter-independent regulation of vimentin expression in mammary epithelial cells by val12 ras and TGFβ

Experimental Cell Research

Volumn 313, Issue 17, 2007, Pages 3718-3728

  Yates, Bradley ^a   Zetterberg, Craig ^a   Rajeev, Vaishali ^b   Reiss, Michael ^b   Rittling, Susan R ^a  

^a FORSYTH INSTITUTE   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

EMT; Metastasis; Suppression; TGF ; Vimentin

Indexed keywords

AZACITIDINE; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN;

ANIMAL CELL; ARTICLE; BREAST EPITHELIUM; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; DNA METHYLATION; METASTASIS; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION;

EID: 34648847327     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.07.026     Document Type: Article

References (60)

1. Perez-Pomares J.M., and Munoz-Chapuli R. Epithelial-mesenchymal transitions: a mesodermal cell strategy for evolutive innovation in Metazoans. Anat. Rec. 268 (2002) 343-351
2. Nawshad A., LaGamba D., and Hay E.D. Transforming growth factor beta (TGFbeta) signalling in palatal growth, apoptosis and epithelial mesenchymal transformation (EMT). Arch. Oral Biol. 49 (2004) 675-689
3. Fuchs I.B., Lichtenegger W., Buehler H., Henrich W., Stein H., Kleine-Tebbe A., and Schaller G. The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res. 22 (2002) 3415-3419
4. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. BioEssays 23 (2001) 912-923
5. Singh S., Sadacharan S., Su S., Belldegrun A., Persad S., and Singh G. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res. 63 (2003) 2306-2311
6. Lang S.H., Hyde C., Reid I.N., Hitchcock I.S., Hart C.A., Bryden A.A., Villette J.M., Stower M.J., and Maitland N.J. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 52 (2002) 253-263
7. Hu L., Lau S.H., Tzang C.H., Wen J.M., Wang W., Xie D., Huang M., Wang Y., Wu M.C., Huang J.F., Zeng W.F., Sham J.S., Yang M., and Guan X.Y. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 23 (2004) 298-302
8. Dandachi N., Hauser-Kronberger C., More E., Wiesener B., Hacker G.W., Dietze O., and Wirl G. Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. J. Pathol. 193 (2001) 181-189
9. Bhowmick N.A., Ghiassi M., Bakin A., Aakre M., Lundquist C.A., Engel M.E., Arteaga C.L., and Moses H.L. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell 12 (2001) 27-36
10. Oft M., Peli J., Rudaz C., Schwarz H., Beug H., and Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10 (1996) 2462-2477
11. Oft M., Akhurst R.J., and Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat. Cell Biol. 4 (2002) 487-494
12. Akhurst R.J. TGF-beta antagonists: why suppress a tumor suppressor?. J. Clin. Invest. 109 (2002) 1533-1536
13. Reiss M. TGF-beta and cancer. Microbes Infect. 1 (1999) 1327-1347
14. Jakowlew S.B. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 25 (2006) 435-457
15. Zavadil J., and Bottinger E.P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24 (2005) 5764-5774
16. Grunert S., Jechlinger M., and Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev., Mol. Cell Biol. 4 (2003) 657-665
17. Rittling S.R., Coutinho L., Amram T., and Kolbe M. AP-1/jun binding sites mediate serum inducibility of the human vimentin promoter. Nucleic Acids Res. 17 (1989) 1619-1633
18. Rittling S.R., and Baserga R. Functional analysis and growth factor regulation of the human vimentin promoter. Mol. Cell. Biol. 7 (1987) 3908-3915
19. Garzon R.J., and Zehner Z.E. Multiple silencer elements are involved in regulating the chicken vimentin gene. Mol. Cell. Biol. 14 (1994) 934-943
20. Salvetti A., Lilienbaum A., Li Z., Paulin D., and Gazzolo L. Identification of a negative element in the human vimentin promoter: modulation by the human T-cell leukemia virus type I Tax protein. Mol. Cell. Biol. 13 (1993) 89-97
21. Bindels S., Mestdagt M., Vandewalle C., Jacobs N., Volders L., Noel A., van Roy F., Berx G., Foidart J.M., and Gilles C. Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene 25 (2006) 4975-4985
22. Chen Y., and Rittling S.R. Novel murine mammary epithelial cell lines that form osteolytic bone metastases: effect of strain background on tumor homing. Clin. Exp. Metastasis 20 (2003) 111-120
23. Ge R., Rajeev V., Ray P., Lattime E., Rittling S., Medicherla S., Protter A., Murphy A., Chakravarty J., Dugar S., Schreiner G., Barnard N., and Reiss M. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin. Cancer Res. 12 (2006) 4315-4330
24. Ge R., Rajeev V., Subramanian G., Reiss K.A., Liu D., Higgins L., Joly A., Dugar S., Chakravarty J., Henson M., McEnroe G., Schreiner G., and Reiss M. Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling. Biochem. Pharmacol. 68 (2004) 41-50
25. Rittling S.R., and Novick K.E. Osteopontin expression in mammary gland development and tumorigenesis. Cell Growth Differ. 8 (1997) 1061-1069
26. Sommers C.L., Heckford S.E., Skerker J.M., Worland P., Torri J.A., Thompson E.W., Byers S.W., and Gelmann E.P. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res. 52 (1992) 5190-5197
27. Rittling S.R., and Feng F. Detection of mouse osteopontin by Western blotting. Biochem. Biophys. Res. Commun. 250 (1998) 287-292
28. Yan W., Vellucci V.F., and Reiss M. Smad protein expression and activation in transforming growth factor-beta refractory human squamous cell carcinoma cells. Oncol. Res. 12 (2000) 157-167
29. Natasha T., Kuhn M., Kelly O., and Rittling S.R. Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone. Am. J. Pathol. 168 (2006) 551-561
30. Kuhn M., Shah S., Natasha T., and Rittling S.R. A mouse model of breast cancer metastasis to the choroid of the eye. Clin. Exp. Metastasis 22 (2005) 685-690
31. Kociok N., Heppekausen H., Schraermeyer U., Esser P., Thumann G., Grisanti S., and Heimann K. The mRNA expression of cytokines and their receptors in cultured iris pigment epithelial cells: a comparison with retinal pigment epithelial cells. Exp. Eye Res. 67 (1998) 237-250
32. Sax C.M., Stover D.M., Ilagan J.G., Zehner Z.E., and Piatigorsky J. Functional analysis of chicken vimentin distal promoter regions in cultured lens cells. Gene 130 (1993) 277-281
33. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev., Genet. 3 (2002) 415-428
34. Baylin S.B., and Ohm J.E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?. Nat. Rev., Cancer 6 (2006) 107-116
35. Chang H.C., Cho C.Y., and Hung W.C. Silencing of the metastasis suppressor RECK by RAS oncogene is mediated by DNA methyltransferase 3b-induced promoter methylation. Cancer Res. 66 (2006) 8413-8420
36. Lund P., Weisshaupt K., Mikeska T., Jammas D., Chen X., Kuban R.J., Ungethum U., Krapfenbauer U., Herzel H.P., Schafer R., Walter J., and Sers C. Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation. Oncogene 25 (2006) 4890-4903
37. Pakneshan P., Szyf M., and Rabbani S.A. Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells. Carcinogenesis 26 (2005) 557-564
38. Valcourt U., Kowanetz M., Niimi H., Heldin C.H., and Moustakas A. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol. Biol. Cell 16 (2005) 1987-2002
39. Jechlinger M., Grunert S., Tamir I.H., Janda E., Ludemann S., Waerner T., Seither P., Weith A., Beug H., and Kraut N. Expression profiling of epithelial plasticity in tumor progression. Oncogene 22 (2003) 7155-7169
40. Thuault S., Valcourt U., Petersen M., Manfioletti G., Heldin C.H., and Moustakas A. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J. Cell Biol. 174 (2006) 175-183
41. Janda E., Lehmann K., Killisch I., Jechlinger M., Herzig M., Downward J., Beug H., and Grunert S. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell Biol. 156 (2002) 299-313
42. Thompson E.W., Paik S., Brunner N., Sommers C.L., Zugmaier G., Clarke R., Shima T.B., Torri J., Donahue S., and Lippman M.E. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J. Cell. Physiol. 150 (1992) 534-544
43. Izmailova E.S., and Zehner Z.E. An antisilencer element is involved in the transcriptional regulation of the human vimentin gene. Gene 230 (1999) 111-120
44. Tester A.M., Ruangpanit N., Anderson R.L., and Thompson E.W. MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin. Exp. Metastasis 18 (2000) 553-560
45. Peinado H., Quintanilla M., and Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J. Biol. Chem. 278 (2003) 21113-21123
46. Pieper F.R., Van de Klundert F.A., Raats J.M., Henderik J.B., Schaart G., Ramaekers F.C., and Bloemendal H. Regulation of vimentin expression in cultured epithelial cells. Eur. J. Biochem. 210 (1992) 509-519
47. Vicart P., Schwartz B., Vandewalle A., Bens M., Delouis C., Panthier J.J., Pournin S., Babinet C., and Paulin D. Immortalization of multiple cell types from transgenic mice using a transgene containing the vimentin promoter and a conditional oncogene. Exp. Cell Res. 214 (1994) 35-45
48. Shin S.Y., Bahk Y.Y., Ko J., Chung I.Y., Lee Y.S., Downward J., Eibel H., Sharma P.M., Olefsky J.M., Kim Y.H., Lee B., and Lee Y.H. Suppression of Egr-1 transcription through targeting of the serum response factor by oncogenic H-Ras. EMBO J. 25 (2006) 1093-1103
49. Watnick R.S., Cheng Y.N., Rangarajan A., Ince T.A., and Weinberg R.A. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3 (2003) 219-231
50. Ordway J.M., Williams K., and Curran T. Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene 23 (2004) 3737-3748
51. Farrell F.X., Sax C.M., and Zehner Z.E. A negative element involved in vimentin gene expression. Mol. Cell. Biol. 10 (1990) 2349-2358
52. Kryszke M.H., Moura-Neto V., Lilienbaum A., Paulin D., and Auclair C. Involvement of histone H4 gene transcription factor 1 in downregulation of vimentin gene expression during skeletal muscle differentiation. FEBS Lett. 491 (2001) 30-34
53. Wu Y., Zhang X., Salmon M., Lin X., and Zehner Z.E. TGFbeta1 regulation of vimentin gene expression during differentiation of the C2C12 skeletal myogenic cell line requires Smads, AP-1 and Sp1 family members. Biochim. Biophys. Acta 1773 (2007) 427-439
54. De Craene B., Gilbert B., Stove C., Bruyneel E., van Roy F., and Berx G. The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. Cancer Res. 65 (2005) 6237-6244
55. Medici D., Hay E.D., and Goodenough D.A. Cooperation between snail and LEF-1 transcription factors is essential for TGF-beta1-induced epithelial-mesenchymal transition. Mol. Biol. Cell 17 (2006) 1871-1879
56. Grotegut S., von Schweinitz D., Christofori G., and Lehembre F. Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J. 25 (2006) 3534-3545
57. Moreno-Bueno G., Cubillo E., Sarrio D., Peinado H., Rodriguez-Pinilla S.M., Villa S., Bolos V., Jorda M., Fabra A., Portillo F., Palacios J., and Cano A. Genetic profiling of epithelial cells expressing e-cadherin repressors reveals a distinct role for snail, slug, and e47 factors in epithelial-mesenchymal transition. Cancer Res. 66 (2006) 9543-9556
58. Comijn J., Berx G., Vermassen P., Verschueren K., van Grunsven L., Bruyneel E., Mareel M., Huylebroeck D., and van Roy F. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 7 (2001) 1267-1278
59. Alexander N.R., Tran N.L., Rekapally H., Summers C.E., Glackin C., and Heimark R.L. N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1. Cancer Res. 66 (2006) 3365-3369
60. Stemmler M.P., Hecht A., Kinzel B., and Kemler R. Analysis of regulatory elements of E-cadherin with reporter gene constructs in transgenic mouse embryos. Dev. Dyn. 227 (2003) 238-245